CUTANA™ for ChIP assays, ChIC and CUT&RUN (pAG-MNase) and epigenetics

Chromatin profiling assays enable the mapping of protein-DNA interactions that influence chromatin modeling and gene expression.
Over the years, Chromatin ImmunoPrecipitation (ChIP) assays became the gold-standard for studying transcription factor–DNA binding interactions, nucleosome dynamics, and epigenetics (ex. histone post-translational modifications (PTMs)). This post aims at introducing the latest evolution of ChIP assays: CUTANA™ CUT&RUN and ChIC assays.

Over the last years, ChIP experts express the need for more sensitivity, faster protocols, and more reproducible results (and ideally starting from less starting cellular material). These expectations led to the emergence of new experimental antibody-based experimental approaches like Chromatin ImmunoCleavage (ChIC) assays, and Cleavage Under Targets and Release Using Nuclease (CUT&RUN) methods.



CUTANA™ New ChIP assays

Based on ChIC / CUT&RUN technologies, CUTANA™ product line (developed by Epicypher and distributed by tebu-bio) is a novel ultra-sensitive genomic mapping assay that uses a proprietary immunotethering approach.

Similar to ChIC and CUT&RUN methods, it allows the fast mapping histone PTMs and chromatin interactors with high resolution.

CUTANA™ ChIP principle and advantages

This new approach leverages a factor specific antibody to tether a fusion of protein A, protein G and micrococcal nuclease (pAG-MNase) to genomic binding sites in intact cells, which is then activated by the addition of calcium to cleave DNA. The assay is performed in less than 4 days.

CUTANA Assay Workflow tebu-bio Epicypher
Fig. 1: ChIP CUTANA ™ Assay Workflow.

Compared to ChIP-seq assay, CUTANA™ assays have:

  1. lower sequencing requirements (Sequencing reads required: 3 million),
  2. improved signal-to-noise, reduced assay time (from cells to data in less than 4 days with < 1day of protocol time)
  3. less starting cellular material (100 cells required only as described by Dirks et al. in 2016 (Clin Epigenetics; 2016 (Nov 21); 8 :122).

CUTANA CUT&RUN outperforms ChIP
Fig. 2: CUTANA™ performances vs. ChIP

CUTANA typical results tebu-bio Epicypher
Fig.3: CUTANA™ assays for ChIC / CUT&RUN outperform ChIP.

Additionally, CUTANA™ assays save 5-10x in sequencing requirements
and generate superior quality data compared to ChIP-seq using as little as 3 million sequencing reads.

Fig. 4: CUTANA™ assays save 5-10x in sequencing requirements.
Comparing data generated from standard ChIP-seq methods and sequencing depth (black) to CUTANA (blue). H3K27me3 and H3K4me3 ChIP-Seq data was sourced from ENCODE. Negative control data (yellow) was generated using a Rabbit IgG antibody in CUTANA. Each dataset of CUTANA was acquired using 0.5 million cells (source Epicypher).

Cells (or nuclei) are immobilized on lectin-coated magnetic beads, permeabilized, and incubated with an antibody to a chromatin target (e.g. histone PTM or chromatin / DNA binding protein). Next, pAG-MNase is added and activated via Ca2+. The clipped chromatin fragments diffuse out, followed by DNA purification and next-generation sequencing.

Overview CUTANA CUT&Run protocol by Epicypher & tebu-bio
Fig. 5: CUTANA™ CUT&RUN workflow

ChIP assays: pAG-MNase now available!

The pAG-MNase enzyme is the first reagent in the CUTANA™ product line and is available now from tebu-bio CUT&RUN & ChIC assays.

Recombinantly produced in E. coli, CUTANA™ pAG-MNase is a fusion of Proteins A and G to Micrococcal Nuclease and contains a C-terminal 6xHis epitope tag. 2 sizes are available:

Coming soon! CUTANA™ pAG-MNase assay kit for ChIC / CUT&RUN, as well as CUTANA ™ pAG-Tn5 enzyme and assay kit for ChIC / CUT&TAG will be released. So stay tuned!

ChIP related products

CUTANA™ is a proprietary technology based on chromatin immunocleavage (ChIC) (US20070009937A1; Schmid et. al, Mol Cell 2004) and cleavage Under Targets and Release Using Nuclease (CUT&RUN) (patent pending; Skene and Henikoff, eLIFE 2017) methodology.

Philippe Fixe, PhD
Written by Philippe Fixe, PhD
Philippe Fixe is Marketing Director at tebu-bio, passionate about innovation and R&D in Life sciences, Biotechnology, Medical research, Drug discovery, and also a keen photographer.